Special Access Scheme Category A

The pathway most people haven't heard of

Roughly 17 people a day were approved for medicinal cannabis access through TGA pathways in 2023. Most commentary focuses on the Authorised Prescriber scheme or the better-known Category B of the Special Access Scheme. Category A sits quietly alongside them, doing a specific and often misunderstood job. So let me explain what it actually is , and isn't.

I've spent the better part of the last year reading TGA guidance documents in a small flat off Torrens Street in Braddon, usually with Trevor (my sourdough starter) doing something alarming on the kitchen bench nearby. The SAS is one of those regulatory constructs that sounds simple in a ministerial press release and gets genuinely complicated the moment you read the actual legislative instrument. Category A is a good example of that.

What the Special Access Scheme actually does

Australia's Therapeutic Goods Administration administers three main pathways for patients to access medicines that aren't on the Australian Register of Therapeutic Goods (the ARTG) or aren't approved for a particular indication. The SAS is one of those pathways. It doesn't sit alone , it works alongside the Authorised Prescriber scheme and clinical trial frameworks under the Therapeutic Goods Act 1989 (Cth).

The SAS exists because the ARTG approval process is rigorous and slow by design. For a medicine that hasn't completed that process , or that's approved elsewhere but not yet here; the SAS provides a structured mechanism for individual patient access. The scheme has three categories. Category A and Category B are the most commonly relevant to cannabis-based medicines. Category C is a separate notification pathway for certain lower-risk listed medicines.

Category A: the serious and life-threatening tier

Category A is specifically for patients who are seriously ill with a condition that is reasonably likely to be life-threatening, or who have a condition causing serious deterioration in quality of life. The TGA's own language from the Therapeutic Goods Act 1989 and its accompanying guidance is precise here: "seriously ill" is a defined concept, not a loose descriptor.

The key structural difference between Category A and Category B is notification. Under Category A, a medical practitioner does not need prior TGA approval to supply an unapproved therapeutic good. Instead, they notify the TGA within 28 days of supply. This is a post-supply notification obligation, not a pre-supply approval requirement. That's worth sitting with for a moment, because it inverts the usual regulatory logic.

The practitioner takes on explicit responsibility for the decision. By notifying under Category A, they are essentially representing to the TGA that the patient meets the serious illness criteria and that the practitioner has made an informed clinical judgement to supply. The TGA's role at this stage is record-keeping and monitoring, not pre-authorisation.

Where cannabis fits into this picture

Medicinal cannabis products, broadly meaning preparations containing cannabidiol or tetrahydrocannabinol, the two most clinically discussed cannabinoids, can be accessed via Category A where a patient meets the serious illness threshold.

Most cannabis-based medicines in Australia fall under Schedule 8 of the Poisons Standard (those containing THC above the exemption threshold) or Schedule 4 (certain CBD-dominant preparations). The scheduling classification affects how the medicine is stored, recorded and dispensed at the pharmacy level, but it doesn't change the Category A notification logic at the TGA level.

Products accessed via any SAS pathway must still meet Good Manufacturing Practice standards. This is one of the aspects of the Australian framework I think gets undersold; unapproved doesn't mean unmanufactured to standard. The "unapproved" designation refers to ARTG listing status, not to whether the product was made under quality controls. The two things are genuinely distinct.

How Category A differs from Category B in practice

Category B requires the practitioner to apply to the TGA before supply, and the TGA assesses the application and either approves or declines. That approval-before-supply model is the more familiar administrative shape for most regulated goods.

Category A flips the sequence. Supply first (with clinical justification), notify after. The practical implication is that Category A is reserved for the most urgent, most serious presentations, where waiting for a Category B determination isn't clinically appropriate. Palliative contexts, or situations where a patient's condition is deteriorating rapidly, are the sorts of scenarios where this pathway becomes relevant.

In my reading, the Category A pathway is sometimes described in patient-facing materials as though it's simply "easier" than Category B. That framing misses the point. It's not easier, it places greater immediate responsibility on the prescribing practitioner, who must be confident the serious illness criteria are genuinely met before supply, because the TGA notification is retrospective. The scrutiny hasn't disappeared; it's arrived after the fact rather than before.

The practitioner's obligations under Category A

A medical practitioner accessing medicines via Category A must:

• Be satisfied the patient is seriously ill with a life-threatening or seriously debilitating condition.
• Notify the TGA within 28 days of first supply, using the TGA's Business Services portal.
• Comply with any state or territory permit requirements that apply separately to Schedule 8 substances; because the TGA's federal framework and the state/territory Poisons legislation operate in parallel, not in place of each other.
• Retain appropriate records consistent with professional and legislative obligations.

That last point about state/territory requirements is one area I reckon causes genuine confusion. The federal SAS notification satisfies TGA obligations, but a Schedule 8 permit from, say, NSW Health or the Victorian Department of Health may still be required depending on the jurisdiction. The two layers don't collapse into each other. Practitioners operating across state lines, or in ACT, where federal and territory obligations interact in their own interesting ways, need to be across both.

What Category A doesn't do

Category A doesn't bypass the requirement for a valid prescriber-patient relationship. It doesn't remove the need for a prescription. It doesn't authorise wholesale distribution or supply to patients who don't individually meet the criteria. And it doesn't mean any product can be supplied; the notification system links to a specific product and a specific patient.

It also doesn't say anything about which cannabinoid compounds are appropriate for which presentations. The TGA's role under the notification model is administrative; clinical appropriateness is entirely the prescriber's domain. Understanding something like the endocannabinoid system and the pharmacology of different preparations, including questions of bioavailability and first-pass metabolism, is the prescriber's work, not the TGA's at the Category A stage.

The numbers and the trend

TGA cumulative data published through 2023 showed that Category B approvals for medicinal cannabis have grown significantly year-on-year since rescheduling changes in 2020 and 2021. Category A notifications are a smaller share of total SAS activity for cannabis, which reflects the threshold; not every cannabis patient presents with a life-threatening condition. The majority of SAS cannabis access sits in Category B, or increasingly via the Authorised Prescriber pathway as more practitioners gain AP status.

This is worth naming plainly: Category A is a narrow pathway used in narrow circumstances. It isn't a general-access route and shouldn't be characterised as one.

Sources

• Special Access Scheme, Category A, TGA, Australian Government
• Accessing medicinal cannabis products; TGA, Australian Government
• Poisons Standard (SUSMP), Federal Register of Legislation, Australian Government
• Medicinal cannabis in Australia: the regulatory framework and evidence base, NCBI/PubMed

, Marcus Hale, Regulatory researcher; TGA & access law